Targovax ASA (GB:0RIS) has released an update.
Circio Holding ASA is gaining industry recognition for its pioneering work in circular RNA technology, drawing attention with five articles published in major life science publications and anticipating more coverage. With a readership exceeding three million, these features highlight Circio’s efforts to establish its circVec platform as a leader in gene therapy. The company’s strategic communications and forthcoming partnerships aim to transform treatment options for patients with limited alternatives.
For further insights into GB:0RIS stock, check out TipRanks’ Stock Analysis page.
